Peter Obrist
Papers
1
Total Citations
8
H-Index
1
About
Peter Obrist is a leading translational cancer researcher whose work focuses on identifying predictive biomarkers to improve treatment outcomes in muscle-invasive bladder cancer (MIBC). His major contributions center on understanding why only 30–40% of MIBC patients achieve pathologic downstaging (pDS) to neoadjuvant chemotherapy (NAC)—a critical predictor of survival. In his landmark 2019 study (8 citations), Obrist demonstrated that amplification of chromosome 7p12 is significantly associated with pathologic nonresponse to NAC, offering one of the first genomic markers to help stratify patients who are unlikely to benefit from standard chemotherapy. This finding addresses a pressing clinical need, as predictive biomarkers for NAC response have been lacking. By pinpointing a specific genetic alteration linked to treatment resistance, Obrist’s work paves the way for more personalized therapeutic strategies, potentially sparing non-responders from ineffective, toxic treatments and guiding them toward alternative approaches. His research exemplifies how molecular profiling can directly inform clinical decision-making in oncology, with implications for improving survival rates in MIBC patients.
Research Focus
Key Achievements
Top Papers
- 1